Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 10:57AM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.54 Insider Own88.17% Shs Outstand701.66M Perf Week-10.79%
Market Cap2.52B Forward P/E- EPS next Y-0.29 Insider Trans0.04% Shs Float82.98M Perf Month-0.96%
Income-614.96M PEG- EPS next Q-0.06 Inst Own4.65% Short Float26.28% Perf Quarter8.61%
Sales0.00M P/S- EPS this Y75.76% Inst Trans-29.21% Short Ratio9.36 Perf Half Y77.97%
Book/sh0.11 P/B32.47 EPS next Y-20.83% ROA-141.84% Short Interest21.81M Perf Year127.53%
Cash/sh0.27 P/C13.54 EPS next 5Y- ROE-601.88% 52W Range1.30 - 5.22 Perf YTD37.74%
Dividend Est.- P/FCF- EPS past 5Y- ROI-339.79% 52W High-31.13% Beta-1.10
Dividend TTM- Quick Ratio9.30 Sales past 5Y-28.65% Gross Margin- 52W Low176.54% ATR (14)0.32
Dividend Ex-Date- Current Ratio9.30 EPS Y/Y TTM-147.47% Oper. Margin0.00% RSI (14)43.53 Volatility6.28% 8.63%
Employees105 Debt/Eq1.37 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price8.00
Option/ShortYes / Yes LT Debt/Eq1.33 EPS Q/Q42.70% Payout- Rel Volume0.23 Prev Close3.57
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsFeb 20 BMO Avg Volume2.33M Price3.60
SMA20-4.58% SMA50-13.93% SMA20032.70% Trades Volume140,524 Change0.70%
Date Action Analyst Rating Change Price Target Change
Mar-26-24Initiated Stifel Buy $8
Jun-28-18Downgrade Janney Buy → Neutral
May-02-18Initiated Janney Buy
Apr-12-18Reiterated Needham Buy $30 → $27
Feb-13-18Initiated BTIG Research Buy $33
Jan-04-18Initiated SunTrust Buy $24
Dec-01-17Resumed H.C. Wainwright Buy $16
Nov-16-16Reiterated RBC Capital Mkts Outperform $26 → $29
Oct-05-16Reiterated Needham Buy $22 → $30
Sep-16-16Initiated H.C. Wainwright Buy $26
Apr-11-24 04:30PM
Apr-10-24 07:00AM
Apr-09-24 04:18PM
Apr-02-24 05:41PM
05:43PM Loading…
Mar-29-24 05:43PM
Mar-22-24 07:00AM
Mar-19-24 09:32AM
Mar-14-24 07:00AM
Mar-05-24 07:00AM
Feb-21-24 08:53AM
Feb-20-24 08:31AM
10:29AM Loading…
Feb-14-24 10:29AM
Feb-07-24 07:00AM
Jan-08-24 09:00AM
Jan-03-24 07:30AM
Nov-08-23 12:27PM
Nov-07-23 09:07AM
Nov-02-23 04:41PM
Oct-31-23 08:00AM
Oct-26-23 08:00AM
Oct-19-23 08:00AM
Oct-16-23 11:01PM
12:43PM Loading…
Sep-29-23 12:43PM
Aug-09-23 10:19PM
Aug-02-23 08:00AM
Jul-11-23 11:48AM
Jun-04-23 08:00AM
Jun-01-23 07:30AM
May-22-23 09:30AM
May-18-23 09:46AM
May-16-23 01:21PM
May-11-23 11:18PM
May-09-23 07:30AM
May-05-23 05:08PM
May-03-23 08:30AM
Mar-09-23 03:42PM
Mar-03-23 08:00AM
Feb-23-23 08:00AM
Feb-01-23 10:25AM
Jan-30-23 08:00AM
Jan-20-23 08:00AM
Jan-05-23 09:59AM
Dec-30-22 01:25PM
Dec-09-22 08:27AM
Dec-08-22 04:45PM
Dec-06-22 09:54AM
Nov-17-22 04:15PM
Nov-12-22 07:10AM
Nov-09-22 08:30AM
Oct-20-22 05:15PM
Oct-18-22 08:16AM
Oct-13-22 08:00AM
Oct-04-22 11:49AM
Oct-03-22 04:37PM
Sep-12-22 09:17AM
Aug-22-22 01:16PM
Aug-20-22 08:37AM
Aug-19-22 11:58AM
Aug-11-22 08:00AM
Aug-09-22 01:37PM
Aug-02-22 09:25AM
Jul-26-22 04:15PM
Jul-18-22 04:05PM
Jul-14-22 11:35AM
Jun-22-22 04:30PM
Jun-03-22 08:30AM
Jun-01-22 08:30AM
May-11-22 04:30PM
May-08-22 09:44AM
Apr-10-22 08:36AM
Mar-17-22 04:14PM
Feb-24-22 04:51AM
Feb-09-22 08:00AM
Jan-25-22 07:30AM
Jan-10-22 08:00AM
Jan-05-22 07:30AM
Dec-31-21 02:30PM
Dec-28-21 04:04PM
Dec-23-21 12:07PM
Dec-21-21 12:40PM
Dec-20-21 02:15PM
Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zanganeh MahkamChief Executive OfficerMar 27 '24Buy3.7254,321201,87424,923,800Mar 27 08:28 PM
Zanganeh MahkamChief Executive OfficerMar 27 '24Buy3.7226,00096,720520,814Mar 27 08:28 PM
Dhingra AnkurChief Financial OfficerMar 26 '24Buy3.75100,000375,000354,958Mar 27 08:27 PM
Zanganeh MahkamChief Executive OfficerMar 26 '24Buy3.7530,000112,50030,000Mar 27 08:28 PM
Dhingra AnkurChief Financial OfficerDec 13 '23Buy2.1720,40044,254254,958Dec 13 04:49 PM
Zanganeh MahkamChief Executive OfficerDec 12 '23Buy2.075,00010,350494,814Dec 13 05:11 PM
Soni Manmeet SinghChief Operating OfficerOct 13 '23Buy1.682,976,1904,999,9992,976,190Oct 16 04:06 PM